Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000180 · ClinicalTrials.gov registry record · Phase 1
AIT-082 Phase 1B Study
A Phase 1 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00000180 is a Phase 1 study that has completed, run by National Institute on Aging (NIA).
The verdict
NCT00000180, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.
Interventions
- DRUG AIT-082
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000180
The ClinicalTrials.gov registry entry for NCT00000180 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AIT-082 is the first listed.
NCT00000180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000180 about?
NCT00000180 is a clinical study titled "AIT-082 Phase 1B Study". AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals wit...
What is the current status of trial NCT00000180?
This trial is currently completed. It is a Phase 1 study. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00000180?
The interventions under investigation include: AIT-082 (DRUG).
Who is sponsoring clinical trial NCT00000180?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.